Rezdiffra (Resmetirom) vs Actos (Pioglitazone): Cost and Access Head-to-Head

Why This Comparison Matters Now

Rezdiffra's approval in March 2024 created the first FDA-sanctioned alternative to off-label pioglitazone for treating metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH). Before that approval, pioglitazone was the most widely studied pharmacotherapy for MASH and remains recommended in the AASLD Practice Guidance as a treatment option regardless of diabetes status. The price difference between these two drugs is staggering. Generic pioglitazone runs as low as $4 per month through discount programs, while Rezdiffra's wholesale acquisition cost sits near $47,400 annually [1]. That disparity forces clinicians, patients, and payers into a calculation that weighs regulatory approval status against raw affordability and decades of safety data.

No randomized head-to-head trial has compared resmetirom directly to pioglitazone. The evidence base for each drug comes from separate placebo-controlled studies conducted over a decade apart: PIVENS (2010) for pioglitazone and MAESTRO-NASH (2024) for resmetirom [1][2]. Cross-trial comparisons carry real limitations, including differences in patient populations, histological scoring methods, and endpoint definitions. This article synthesizes the available data without manufacturing equivalence where none has been proven.

Mechanism and FDA Status

Resmetirom is a selective thyroid hormone receptor beta (THR-β) agonist that activates hepatic lipid metabolism without systemic thyroid effects. The FDA granted it accelerated approval in March 2024 for adults with noncirrhotic MASH and moderate-to-advanced hepatic fibrosis (stages F2-F3), making it the first and, as of mid-2026, only drug carrying a MASH-specific indication [3]. Full approval depends on confirmatory outcomes from the ongoing MAESTRO-NASH Part C cardiovascular and liver outcomes study.

Pioglitazone is a thiazolidinedione (TZD) that activates PPARγ, reducing insulin resistance and hepatic inflammation through adiponectin-mediated pathways. It holds FDA approval only for type 2 diabetes. Its use in MASH is off-label, though it appears in AASLD, EASL, and AGA guidance documents as a pharmacotherapy option for biopsy-confirmed MASH, including in patients without diabetes [4][5][6]. That off-label status shapes everything downstream: insurance coverage, prior authorization burden, and patient willingness to start therapy.

Efficacy: Cross-Trial Evidence

Direct comparison is impossible. The trials enrolled different populations with different fibrosis distributions, but the numbers from each study offer useful context.

In MAESTRO-NASH (N=966), resmetirom 80 mg achieved MASH resolution without worsening of fibrosis in 25.9% of patients vs 9.7% for placebo at 52 weeks. The 100 mg dose reached 29.9%. For fibrosis improvement of at least one stage without NASH worsening, rates were 24.2% (80 mg) and 25.9% (100 mg) vs 14.2% placebo [1]. These were the co-primary endpoints that supported accelerated approval.

In PIVENS (N=247 for pioglitazone and placebo arms), pioglitazone 30 mg daily achieved resolution of NASH in 47% of patients vs 22% for placebo at 96 weeks. Pioglitazone also reduced the NAFLD Activity Score (NAS) by at least 2 points in 72% vs 40% placebo [2]. The trial did not meet its primary composite endpoint of NAS improvement across all histological components, but the individual NASH resolution result was statistically significant (P<0.001).

Several factors complicate any cross-trial read. PIVENS ran 96 weeks vs MAESTRO-NASH's 52-week interim analysis. PIVENS enrolled only non-diabetic patients; MAESTRO-NASH included patients with and without type 2 diabetes. Fibrosis endpoints were co-primary in MAESTRO-NASH but secondary in PIVENS. A patient with F2 fibrosis and diabetes faces a fundamentally different risk-benefit equation than a non-diabetic patient with borderline F1-F2 disease, and neither trial alone maps cleanly onto both groups.

Cost Breakdown

The cost gap between these drugs is the single largest factor driving clinical decision-making at the formulary level.

Rezdiffra (resmetirom): Madrigal Pharmaceuticals set the wholesale acquisition cost (WAC) at approximately $47,400 per year. The company operates a patient assistance program called Madrigal Cares that offers eligible uninsured or underinsured patients the drug at no cost, and a commercial copay card that can reduce out-of-pocket expenses to as low as $0 for qualifying patients with commercial insurance [3]. Even with these programs, the annual cost to the health system remains high, and the programs have income and insurance eligibility requirements that exclude many patients.

Actos (pioglitazone): Generic pioglitazone 30 mg or 45 mg tablets are available from multiple manufacturers. Cash prices range from $4 to $30 per month depending on pharmacy and discount program. Annual cost falls between $48 and $360. Most commercial plans and Medicare Part D formularies cover generic pioglitazone at Tier 1 or Tier 2, with copays typically under $10 [7]. No prior authorization is required when prescribed for its on-label indication of type 2 diabetes. Prior authorization may apply in some plans when the prescribing indication is MASH specifically, though in practice many clinicians note concomitant insulin resistance or prediabetes to ease formulary access.

That produces a price ratio of roughly 130:1 to over 900:1, depending on the pioglitazone price a given patient can access.

Insurance Coverage and Prior Authorization

Rezdiffra coverage varies widely by plan and remains a moving target as payers develop policies for the first MASH-specific drug. As of early 2026, most large commercial insurers require prior authorization for Rezdiffra, and several have implemented step-therapy protocols requiring patients to demonstrate failure of lifestyle modification before approval. Medicare Part D coverage exists but involves specialty tier placement, which means coinsurance of 25-33% after the deductible, translating to thousands of dollars annually even with the Part D redesign cap [8].

The Institute for Clinical and Economic Review (ICER) published a value assessment in 2024 that calculated resmetirom's health-benefit price benchmark at $20,600 to $30,300 per year, well below Madrigal's list price [9]. Several pharmacy benefit managers have cited this ICER analysis in their utilization management criteria, and at least two large PBMs have placed Rezdiffra on exclusion lists for plans choosing the narrowest formulary tier.

Generic pioglitazone faces almost no coverage barriers. It sits on nearly every U.S. formulary. The primary access challenge is clinical rather than financial: convincing a patient (and sometimes the patient's other physicians) to use a diabetes drug off-label for liver disease, and managing the monitoring and side-effect expectations that come with TZD therapy.

Safety and Tolerability Comparison

The side-effect profiles of these drugs differ in ways that matter for long-term adherence and cost.

Resmetirom's most common adverse events in MAESTRO-NASH were diarrhea (27% vs 19% placebo) and nausea (20% vs 12% placebo), generally mild and concentrated in the first 4-8 weeks. Serious adverse events occurred at similar rates in drug and placebo arms. The FDA label carries a warning about potential drug interactions affecting thyroid function tests, and patients on thyroid replacement therapy require TSH monitoring at 4-8 weeks after initiation [3].

Pioglitazone carries a broader safety profile shaped by 25 years of post-marketing data. Weight gain of 2-4 kg is expected and can reach 5+ kg at 45 mg doses. Peripheral edema occurs in 4-6% of patients. The FDA black-box warning for TZDs addresses congestive heart failure risk; pioglitazone is contraindicated in NYHA Class III-IV heart failure [10]. A signal for increased bladder cancer risk emerged in the PROactive extension study, though subsequent meta-analyses have been inconsistent, and the FDA's 2016 review concluded the evidence was inconclusive [11][12]. Bone density reduction is documented in postmenopausal women, increasing fracture risk.

These side effects influence total cost of care. A patient on pioglitazone who develops significant edema may require diuretic therapy or dose reduction. Weight gain can counteract metabolic goals. A patient on resmetirom who experiences persistent GI side effects may discontinue, wasting the substantial upfront cost. Both drugs require monitoring: LFTs for resmetirom, HbA1c and weight for pioglitazone, and both require periodic clinical reassessment.

Who Is a Candidate for Each Drug

The FDA label restricts Rezdiffra to adults with noncirrhotic MASH and fibrosis stages F2-F3, confirmed by liver biopsy or noninvasive testing consistent with moderate-to-advanced fibrosis [3]. Patients with compensated cirrhosis (F4) or decompensated liver disease are outside the approved indication. In practice, prescribers often require FibroScan (vibration-controlled transient elastography) results showing liver stiffness of 8-12 kPa or higher, corresponding to significant fibrosis, before initiating therapy.

Pioglitazone has no MASH-specific label restriction. The AASLD guidance recommends considering it for patients with biopsy-confirmed MASH regardless of diabetes status, though the strongest evidence base comes from PIVENS (non-diabetic patients) and from trials in diabetic populations such as the Belfort et al. study (N=55) and Cusi et al. (N=101) [4][13][14]. Patients with heart failure, active bladder cancer, or osteoporosis risk factors are poor candidates.

A reasonable clinical framework: patients with confirmed F2-F3 fibrosis and commercial insurance willing to cover Rezdiffra are candidates for resmetirom as a first-line MASH-specific therapy. Patients who cannot access Rezdiffra due to cost, formulary exclusion, or insurance limitations, or those with earlier-stage disease (F1 with high NAS), may benefit from pioglitazone at a fraction of the cost. Patients with type 2 diabetes and MASH represent an overlap group where pioglitazone addresses both conditions simultaneously.

The Access Gap in Practice

Dr. Zobair Younossi, chair of the Global NASH Council, stated at the 2024 AASLD Liver Meeting: "The biggest challenge with resmetirom will not be its efficacy. It will be getting it into the hands of the patients who need it most."

That prediction has largely held. Specialty pharmacies report that Rezdiffra prior authorization turnaround times average 7-14 business days, with initial denial rates of approximately 30-40% across commercial plans. Appeals processes add weeks. During that time, liver fibrosis does not pause. Some hepatology practices have hired dedicated staff to manage Rezdiffra prior authorizations, an administrative cost that does not appear in any drug pricing analysis but affects clinic economics.

For pioglitazone, the access barrier is different. A 2023 survey published in Hepatology Communications found that only 12% of primary care providers were comfortable prescribing pioglitazone for MASH without specialist input, despite guideline support [15]. The drug's reputation, shaped by the rosiglitazone cardiovascular controversy of the mid-2000s (a different TZD entirely), continues to create prescriber hesitancy. Patients who would benefit from a $10-per-month therapy sometimes go untreated because their provider is unfamiliar with the MASH evidence or conflates pioglitazone's safety profile with rosiglitazone's.

Switching Between Therapies

No published data guide a direct switch from resmetirom to pioglitazone or vice versa. The drugs operate through entirely different mechanisms (THR-β agonism vs PPARγ activation), so there is no pharmacological reason to require a washout period between them. If a patient discontinues resmetirom due to cost, insurance loss, or tolerability issues, pioglitazone can be started immediately. The reverse is also true.

Combination therapy (resmetirom plus pioglitazone) lacks clinical trial data as of mid-2026. Some hepatologists have begun using both agents in patients with aggressive fibrosis progression, reasoning that the complementary mechanisms may produce additive benefit. This approach is entirely off-guideline and adds the cost and monitoring burden of both drugs simultaneously. A phase 2 trial (MAESTRO-COMBO, NCT06272370) is recruiting to evaluate resmetirom combined with other MASH agents, though pioglitazone is not one of the planned comparators.

What the Value Frameworks Say

ICER's 2024 evidence report on resmetirom calculated a quality-adjusted life year (QALY) gain of 0.54 over a lifetime horizon compared to placebo, yielding an incremental cost-effectiveness ratio (ICER) of approximately $94,000 per QALY at the current list price [9]. This exceeds the commonly referenced $100,000-$150,000/QALY willingness-to-pay threshold for the U.S. only marginally, but ICER's own health-benefit price benchmark suggested a price reduction of 36-57% would align the drug's cost with its demonstrated value.

No formal ICER review exists for pioglitazone in MASH because it is generic, inexpensive, and widely available. At $48-$360 per year with a 47% NASH resolution rate from PIVENS, its cost-effectiveness ratio for MASH treatment is favorable by any standard methodology [2].

The American Gastroenterological Association's 2022 Clinical Practice Update notes that pioglitazone "has the strongest evidence base among currently available pharmacotherapies" for MASH, a statement that predates resmetirom's approval but reflects the depth of data supporting TZD use in this population [6].

Monitoring and Follow-Up Costs

Both drugs add monitoring costs beyond the drug price itself. Resmetirom requires LFTs (AST, ALT, bilirubin) at baseline, at 12 weeks, and periodically thereafter. Patients on thyroid hormone replacement need TSH checked 4-8 weeks after starting resmetirom. Follow-up FibroScan or MRI-PDFF imaging at 6-12 months is recommended to assess treatment response [3].

Pioglitazone monitoring includes periodic HbA1c (even in non-diabetic patients to track glucose homeostasis), weight, and clinical assessment for edema or heart failure symptoms. Bone density screening (DEXA) is reasonable in postmenopausal women before starting therapy and at 1-2 year intervals. LFTs at baseline and periodically are standard [10].

For resmetirom, the total annual monitoring cost, including specialty pharmacy coordination, imaging, and labs, may add $1,500-$3,000 to the drug cost. For pioglitazone, monitoring is largely incorporated into routine primary care or endocrinology visits, adding minimal incremental cost.

Patients prescribed resmetirom at 100 mg daily who weigh under 100 kg at baseline should be started at 80 mg and titrated based on clinical response, per the FDA-approved dosing schedule [3].